NCT07448038: A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- State
- Under way
- Phase
- Phase 2
- People
- 162 planned
- Started
- 5 Jun 2026
- Primary completion
- 31 Jan 2028
- Arms
- Selnoflast
- Results
- None posted
- 4 Mar 2026: Trial registered
- 5 Jun 2026: Trial started